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ABSTRACT
The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-zoster and herpes zoster is well
documented, as are many of the mutations that contribute to the attenuation of the vOka virus for replication in skin. At least
three different preparations of vOka are marketed. Here, we show using deep sequencing of seven batches of vOka vaccine (in-
cluding ZostaVax, VariVax, VarilRix, and the Oka/Biken working seed) from three different manufacturers (VariVax, GSK, and
Biken) that 137 single-nucleotide polymorphism (SNP) mutations are present in all vaccine batches. This includes six sites at
which the vaccine allele is fixed or near fixation, which we speculate are likely to be important for attenuation.We also show that
despite differences in the vaccine populations between preparations, batch-to-batch variation is minimal, as is the number and
frequency of mutations unique to individual batches. This suggests that the vaccine manufacturing processes are not introduc-
ing newmutations and that, notwithstanding the mixture of variants present, VZV live vaccines are extremely stable.
IMPORTANCE
The continued success of vaccinations to prevent chickenpox and shingles, combined with the extremely low incidence of ad-
verse reactions, indicates the quality of these vaccines. The vaccine itself is comprised of a heterogeneous live attenuated virus
population and thus requires deep-sequencing technologies to explore the differences and similarities in the virus populations
between different preparations and batches of the vaccines. Our data demonstrate minimal variation between batches, an impor-
tant safety feature, and provide new insights into the extent of the mutations present in this attenuated virus.
Primary infection with the varicella-zoster virus (VZV) causeschickenpox (varicella), during which the virus also establishes
lifelong latency in sensory ganglia (reviewed in reference 1). Re-
activation of the virus causes herpes zoster in up to 30% of infected
individuals and carries the potential for a range of serious compli-
cations including postherpetic neuralgia, stroke, keratitis, and
meningoencephalitis (2–5).
Since 1995, a live attenuated VZV vaccine (vOka) has been
routinely administered to healthy children aged 12 to 18 months
in the United States with significant success (6). Similar programs
have since been established in a number of other countries, in-
cluding Canada, Germany, Greece, Uruguay, and Australia (re-
viewed in reference 1). The most common VZV (vOka) vaccine
preparations for the prevention of varicella are VarilRix (GSK),
VariVax (Merck), and OkaVax(Biken), while a high-dose prepa-
ration (19,000 PFU versus 1,350 PFU) called ZostaVax (Merck) is
routinely used to prevent episodes of herpes zoster. The vaccine
itself was derived, by attenuation, from a wild-type virus (pOka)
isolated from a small child (Oka) with primary varicella. Attenu-
ation was achieved through serial passage in human embryo fibro-
blasts, guinea pig embryo fibroblasts, and WI-38 human diploid
cells to generate the vOka/Biken seed virus (7). At least three vac-
cine preparations derived from this seed stock are currently in use
(Fig. 1) (8). A comparative sequence analysis, using overlapping
PCR and Sanger sequencing, of pOka and a batch of the Biken
varicella vaccine (lot V-65, made in late 1990s) revealed 42 single-
nucleotide polymorphism (SNP) differences between the wild-
type and attenuated Oka strains, as well as variations in the lengths
of the small repetitive R1, R3, R4, and OriS regions of the genome
(9). Furthermore, this study established that the vOka seed com-
prises a heterogeneous population of vOka haplotypes. The
SNP(s) responsible for attenuation has not been completely
worked out, although current data suggest that the fixed vaccine
SNP at position 106262 (R958G, ORF62), a very high frequency
SNP at position 107252 (S628G, ORF62), and a third SNP at po-
sition 562 (*130R, ORF0) are important (9–17). In the context of
a viral population, we are using the term SNP to indicate sites at
which either (i) two or more alleles are present within that popu-
lation or (ii) the fixed allele at a site differs from the parental
sequence.
By analyzing vaccine allele frequencies at limited a subset of
SNPs, we and others have observed that the vaccine allele fre-
quency is lower in VariVax batches than VarilRix batches (18–20).
More recently, deep sequencing of Merck VariVax vaccine batches
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using Roche 454 (21) and Illumina technologies (22) has identi-
fied more than 100 new variant sites, some unique to a single
VariVax preparation and some common to multiple VariVax
preparations. For most but not all of the new sites, the vaccine
allele frequency is typically below 20%. However, it remains un-
clear how many of these sites are shared by different vaccine prep-
arations (i.e., which sites are also present in Oka/Biken and GSK
VarilRix vaccines) and therefore potentially contribute to vaccine
attenuation.
To investigate this, we performed comparative analyses of vac-
cine batches produced by GSK (VarilRix) and Merck (VariVax
and ZostaVax), as well as the Biken working seed stock (itself
derived from the vOka/Biken seed virus). Our findings include the
identification of 137 core SNPs that are shared by all vaccine
batches and the Biken working seed stock (which includes 40/42 of
the previously reported variant sites). We also demonstrate that
while the heterogeneity of vaccine populations differs markedly
between GSK and Merck preparations, variation between batches
of vaccine from the same manufacturer is minimal. Finally, we
examine whether differences in the vaccine allele frequencies at
shared variant sites could potentially result in differences in vac-
cine efficacy.
MATERIALS AND METHODS
Vaccine collection. Three batches of the VariVax live attenuated VZV
vaccine preparation were collected in 2008 (VVAG [USA]), 2010 (VV10
[United Kingdom]), and 2012 (VV12 [United Kingdom]). One batch of
ZostaVax was obtained in 2015 (ZV15 [United Kingdom]). Two batches
of GSK were collected in 2008 (VL08 [United Kingdom]) and 2013 (VL13
[United Kingdom]). One batch of the Oka/Biken working seed stock was
kindly provided by Y. Gomi in 2014. In all cases, batch and lot numbers
were used to verify all vaccines as independent preparations (Table 1).
Library construction, targeted enrichment, and sequencing. Total
DNA was extracted from each sample using the QiaAMP DNA minikit
(Qiagen) according to the manufacturer’s instructions, and DNA was
quantified using a Qubit HS DNA assay (Invitrogen). Sequencing libraries
were constructed using 200 ng of input DNA in accordance with the
standard SureSelect XT v1.5 (Agilent) protocol, and enrichment for VZV
sequences was performed as described previously (23). Samples were se-
quenced across several Illumina MiSeq runs according to availability.
FIG 1 Overview of varicella vaccine production. Shaded cells indicate the preparations obtained and used in this study. HEL, human embryonic lung cell
cultures; GPE, embryonic guinea pig cell cultures; WI38, human diploid cell cultures; MRC5, human diploid cell cultures. Subscript numbers indicate passage
levels. Superscripts: a, information was obtained from a previous study (8); b, information obtained from Merck Product information IPC-VRV3-I-032008. *,
Unknown number of passage levels in MRC5 cells. Where passage levels are given next to an asterisk (*), these have been inferred from superscript sources “a”
and “b” above. World Health Organization guidelines indicate a limit for Oka strain varicella vaccine at passage level 38; hence, the final levels of passage in MRC5
cells can be estimated (8).
TABLE 1 Overview of vaccine batches used in this study
Sample ID Vaccine preparation Yr of manufacture Batch no. Source country
VV10 VariVax 2010 NL13110 United Kingdom
VVAG VariVax 2009 1526X USA
VV12 VariVax 2012 G007544 United Kingdom
ZV15 ZostaVax 2015 L029213 United Kingdom
VL08 VarilRix 2008 A70CA882A/AD06A508A United Kingdom
VL13 VarilRix 2013 Unavailable United Kingdom
Biken Oka/Biken working seed 2008a M6002 Japan
a Used for vaccine manufacturing from 2011 to 2015.
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Genome assembly and variant calling. Adaptor sequences and low
quality bases were trimmed from read data using Trim Galore (http:
//www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Data sets
were aligned against VZV strain Dumas (NC_001348) using BWA
(24). The resulting alignments were processed using Picard (http:
//broadinstitute.github.io/picard) and the GATK Toolkit (25) to remove
duplicate reads and perform local realignment. SAMTools (26) was sub-
sequently used to generate pileup files for each sample. A consensus se-
quence for each data set was called using a custom PERL module. Variant
profiling for each data set was performed using VarScan v2.2.11 (27) with
the following parameters: a basecall quality of20, a read depth of50,
and independent reads supporting minor allele of 2 per strand. In ad-
dition, variant calls showing a directional strand bias of 0.85 were ex-
cluded from further analyses. Consensus sequences were generated for
each rash sample, but iterative repeat regions (OriS, R1, R2, R3, R4, and
R5) and the terminal repeat region were trimmed before further analysis.
Accession number(s). All sequencing data are available from the Eu-
ropean Nucleotide Archive under study accession number PRJEB14639.
RESULTS
Comparative sequencing ofMerck, GSK, andBiken vaccines re-
veals a core set of 137 SNPs. Deep sequencing of seven batches of
vaccine was performed using sequence libraries enriched for VZV
DNA (22, 23). Full details of the vaccine batches sequenced are
shown in Table 1. After quality control of the sequence data,
paired-end reads were aligned to the VZV reference strain Dumas
(NC_001348 [28]) and subjected to deduplication and local re-
alignment, after which intrasample population profiles were pro-
duced. Using entropy as a measure of population diversity, we
observed an increased heterogeneity in Merck vaccine batches
when contrasted against GSK vaccine batches and the Oka/Biken
working seed, both of which are comparably diverse (Fig. 2A). We
subsequently compiled a list of 481 variant sites (SNPs at which
two alleles are present) that are detected in at least some genomes
obtained from each of the vaccine batches“ (see Table S1 in the
supplemental material) and revealed a conserved core of 137 SNPs
that are present in all vaccine batches and the Oka/Biken working
seed (Fig. 2B). No unique variable sites were identified in the Oka/
Biken working seed, whereas just five unique variable sites were
identified in the GSK vaccine batches. In contrast, 292 unique
variable sites were identified in the Merck vaccine batches, which
presumably reflects the differences in the vaccine production pro-
cess. Of the 137 core sites (Fig. 3; see also Table S2 in the supple-
mental material), 57 encoded nonsynonymous changes and 27
encoded synonymous changes, while 53 encoded mutations in
FIG2 (A) vOka population heterogeneity is highest in Merck preparations (VariVax and ZostaVax). Entropy was used as the measure of the population diversity
within a sample, with greater entropy indicating greater diversity. (B) A total of 137 core SNPs were identified in all vaccine batches, one or more of which are
assumed to contribute to attenuation. SNPs that are not shared between all batches (or are unique to a manufacturer) are presumed to have been gained or lost
during production of the individual manufacturers master and/or working seed stocks. Note that the greater heterogeneity observed in Merck vaccine batches
(see panel A) is derived from the additional 292 biallelic sites present only in VariVax and ZostaVax batches.
FIG 3 Circos plot showing the location of the core 137 variant sites common
to all vOka-derived preparations. Vaccine allele frequencies are shown by the
length of the red (nonsynonymous), blue (synonymous), and black (noncod-
ing) lines, all overlaid on a backbone (gray) indicating the exact position of the
SNP. Triangular headers indicate sites previously identified by Gomi and co-
workers (17). The outer band shown the canonical genome structure (UL-
IRL-US-TRL) with the IRL and TRL shown in lilac and the R1, R2, R3, R4, R5,
and OriS repeat regions shown in black. Forward and reverse coding ORFs are
shown as orange blocks. Relevant ORF numbers are indicated around the
outside of the plot.
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noncoding regions. A total of 20.54% of the core sites were located
within ORF62, while no other open reading frame (ORF) con-
tained more than 4.38% (median, 0.73%) of the core sites.
At only 32/137 sites was the vaccine allele present at 50%
frequency in one or more preparations (14 nonsynonymous, 11
synonymous, and 7 noncoding mutations). This increases to 52/
137 sites at 25% and 77/137 sites at 10%. Of note, at only a
single site (106262, R958G in ORF62) was the vaccine allele fixed
at 100% (i.e., there is no evidence of any haplotypes in any vaccine
mixture carrying a different allele). In addition, the vaccine allele
was present at 98% at three additional sites, two of which en-
coded synonymous mutations (105705, A1143; 108111, P341),
with one nonsynonymous SNP (107252, S628G), all in ORF 62. A
total of 40/42 of the original SNP differences reported between the
Oka/Biken vaccine (lot V-76) and pOka (9) were accounted for
within the set of core sites. Those absent comprised two sites en-
coding synonymous mutations at 84091 and 106710. The former
is absent in all Merck batches sequenced to date but present in
Biken and GSK batches, while the latter is absent in all batches,
suggesting that this was a polymorphism specific to the Oka/Biken
vaccine preparation used in that study.
Minimal batch-to-batch variation exists in GSK and Merck
vaccine batches. Batch-to-batch variation between two VarilRix
batches (2008 and 2013) and two VariVax batches (2008 and
2012) is minimal, as demonstrated by the R2 correlation values
(0.988 and 0.971, respectively) (Fig. 4A and B). Similarly, a highR2
correlation score (0.945) was observed between the 2012 batch of
VariVax and the 2015 batch of ZostaVax (Fig. 4C). While up to 26
variant sites were unique to any given batch of vaccine, none of
these exceeded 32% frequency (median, 1.58%).
Merck vaccine batches are distinct from GSK vaccines and
the Biken working seed vaccine. A high correlation (R2 0.981)
in vaccine allele frequencies was also evident when we compared
vaccines produced by GSK and the Biken working stock (Fig. 4D).
By comparison, the correlation between Merck vaccines and the
Biken working stock (and by extension, the correlation between
Merck and GSK vaccines) was markedly lower, whether consider-
ing all sites (R2 0.689, Fig. 4E) or just the core sites (R2 0.697,
Fig. 4F). Focusing purely on the core variant sites (Fig. 5), the
mean vaccine allele frequencies were significantly lower in Merck
vaccines than in GSK vaccines (P 0.02, Mann-Whitney U test)
and the Biken working seed (P 0.04).
DISCUSSION
Commercial VZV Oka vaccines, aimed at preventing chickenpox
and shingles, are available from three manufacturers (GSK, Biken,
and Merck). All three preparations are derived from the live at-
tenuated vOka seed stock originally produced in 1972. The first
comparative sequencing study comparing the wild-type virus
(pOka) and the attenuated virus strain (Biken vOka) revealed 42
SNP differences (9) but was hampered by the use of older and less
sensitive sequencing technologies. By combining Illumina se-
quencing with SureSelect enrichment, we have confirmed the
presence of 40 of these SNPs and identified a further 97 SNPs to
obtain a core set of 137 SNPs that are common to all vaccine
preparations and therefore likely to have been present in the orig-
inal attenuated virus stock. For most of these, the vaccine allele
frequency is less than 20% However, six sites (560, *130R, ORF0;
105544, V1197A; 105705, A1143; 106262, R958G; 107252, S628G;
and 108111, P341 [all ORF62]) are consistently fixed (106262) or
near fixation (90%) in all three preparations, three of which
(560, 106262, and 107252) have been shown to be important for
attenuation, although heterogeneity (3% wild-type allele fre-
quency) at position 106262 in one batch of VariVax vaccine has
been reported using a TA cloning methodology (19). Another 22
are present at frequencies of20% in all three. Two of these sites,
both located in intergenic regions (positions 105010 and 110379),
have not previously been reported. Four of the core sites (560,
*130R, ORF0; 105356, I1260V; 106262, R958G; and 107252,
S628G [all ORF62]) are shared with VZV strain Ellen (see Table S2
in the supplemental material), which has been shown to be atten-
uated for growth in SCID-hu mice skin explants (11), although, it
is not known whether the Ellen phenotype is clinically attenuated.
One site, position 560 (*130R), is also shared with the Korean
SudaVax preparation, which is derived from a Korean wild-type
strain using the same methodology as that used for the original
vOka (29). However, no other vaccine-associated mutations have
been described for SudaVax, and there are no data confirming that
this vaccine is attenuated either in vitro or clinically.
Vaccine allele frequencies at the core sites differ between vac-
cine preparations from different manufacturers, with vaccine al-
leles being present at a higher frequency for 67.8% of the core sites
in the GSK and Biken vaccines versus the Merck vaccine. This
finding supports previous data showing higher vaccine allele fre-
quencies for 15 loci in the GSK vaccine compared to the Merck
vaccine (20) and probably reflects differences in manufacturing
process. For instance, the GSK vaccine underwent a series of ter-
minal dilutions during production of the Oka/GSK seed stock
(Fig. 1), resulting in a bottleneck that removed many low-fre-
quency vaccine alleles from the population.
However, more than 82% of the 292 variants specific to Merck
vaccines were present in two or more batches. This, together with
the finding that at least 158 of the 292 variant alleles have previ-
ously been observed in vaccine rash cases after inoculation with
VariVax vaccines, suggests that most of these mutations were ac-
quired during the production of the working seed lot that cur-
rently forms the basis of all batch production and not during vac-
cine batch production itself (22). Thus, batch-to-batch variation
is low for both Merck and GSK vaccine preparations (Fig. 4A and
B), reflecting the success of the tight controls on working practices
for live vaccine production. Importantly, most of the mutations
seen in vaccine preparations from all three manufacturers are pre-
existing, and new mutations appear to arise rarely and remain at
low frequency. Moreover, the conservation in variant populations
extends between vaccine preparations (Fig. 4C) from Merck used
for vaccinating against chickenpox (VariVax) and those used to
prevent herpes zoster (ZostaVax), despite a 14-fold difference in
PFU between the preparations.
None of the three preparations have been directly compared
for vaccine efficacy or adverse events. However, higher serocon-
version rates have been reported for the Merck (VariVax) vaccine
compared to the GSK (VarilRix) vaccine (30, 31). Similarly, a
comparative study of vaccine effectiveness following an outbreak
at a nursery reported a higher risk of breakthrough disease in
individuals who had received the GSK vaccine compared to those
who had received the Merck vaccine (32). Thus, the higher core
vaccine allele frequencies in the GSK vaccine may have resulted in
slight reduction of immune responses and protection. This sug-
gests that loci other than the six sites that are fixed or near fixation
in both preparations may contribute to vaccine attenuation. How-
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FIG 4 (A to F) Comparison of vOka vaccine allele frequencies between two batches of VarilRix (2008 and 2013, 238 SNPs) (A), between two batches of VariVax
(2008 and 2012, 466 SNPs) (B), between one batch of VariVax (2012) and one batch of ZostaVax (2015) (466 SNPs) (C), between GSK VarilRix (average) and
Biken working seed (188 SNPs) (D), between Merck VariVax/ZostaVax (average) and Biken working seed (475 SNPs) (E), and between Merck VariVax/ZostaVax
(average) and Biken working seed (F) at the core 137 sites only. Best-fit trendlines are shown in black and are compared to the “(0, 1)” line, shown in red. The axes
indicate the percent frequency of the vOka allele in that preparation.











ever, although there are considerable data on these available for
the Merck preparation, data for adverse events following the GSK
and Biken preparations are limited or absent, and therefore no
conclusions can be drawn.
In summary, we have produced a definitive catalogue of the
mutations present in vOka vaccine preparations from three man-
ufacturers. Although differences between the vaccines do exist,
there appear to be a substantial number of vaccine sites that are
shared, including one at which the vaccine allele is fixed and five at
which the vaccine allele is near fixation (90% frequency) in all
three. We propose that these are critically important for attenua-
tion. However, limited data from clinical and serological studies
provide strong support for the notion that other sites in the ge-
nome are also likely to contribute (11). Despite differences be-
tween vaccine preparations, we confirm that there is little batch-
to-batch variation for two of the vaccine preparations tested,
suggesting that new mutations arising during manufacture of the
vaccine batches being few in number and at low frequency are
unlikely to impact vaccine safety and efficacy.
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